Mylan, Pfizer Say EpiPen Antitrust Suits Don't Need MDL

By Dani Kass (May 18, 2017, 1:59 PM EDT) -- Mylan NV and Pfizer Inc. on Wednesday each urged the Judicial Panel on Multidistrict Litigation not to consolidate antitrust litigation against the drugmakers, arguing the majority of cases are already working together in Kansas to make the litigation work, so the move is unnecessary....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!